Innovent Starts China Trials of Novel Anti-Inflammatory Biologic

Suzhou Innovent Bio has started a China Phase I trial of a novel anti-inflammatory drug. IBI112 is a recombinant anti-interleukin 23p19 subunit antibody injection that is aimed at psoriasis, inflammatory bowel disease (IBD) and other autoimmune diseases. The trial will evaluate the safety and tolerability of the candidate in addition to PK/PD when IBI112 is administered as a single subcutaneous or IV dose in healthy individuals. More details.... Stock Symbol: (HK: 01801) Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.